ERBB2 and breast carcinoma: The results from our prophylactic crofelemer- neratinib dog study also buttress the results observed in a prophylactic crofelemer study in HER2-positive breast cancer patients receiving trastuzumab, pertuzumab, with a taxane, with or without carboplatin, called the HALT-D study [9].